Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the webspellchecker domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/gulfindex35/public_html/ijpcs.net/wp-includes/functions.php on line 6131
Drug Review: Terlipressin – IJPCS

Drug Review: Terlipressin

International Journal of Pharmacology and Clinical Sciences, 2023, 12, 3, 138–139.
Published: February 2024
Type: Research Article
Authors: Juman Alsaab
 
Author(s) affiliations:

Juman Alsaab,
Pharm D Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Registrations: It had been registered in the following countries: United Kingdom (UK), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); TERLIVAZ ® Registration number (SA); 11-367-07. Insurance Drug Formulary (SA); Covered. General Information: Registered Company: Mallinckrodt hospital products inc. Regulatory Status: RX. Mechanism of Action: Prodrug The active form is lysine vasopressin, the non-selective agonist of both V1 (smooth muscles of the arterial vasculature in the splanchnic region) and V2 receptors (collecting ducts of renal tubules). Read more…